Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Kyowa Hakko Kirin Nabs ProStrakan
by Lisa M. Jarvis
February 28, 2011
| A version of this story appeared in
Volume 89, Issue 9
Kyowa Hakko Kirin has agreed to pay roughly $470 million for Scottish specialty pharmaceutical firm ProStrakan Group. Tokyo-based KHK says the deal was driven by the potential to quickly expand in the U.S. and Europe. ProStrakan brings clinical and regulatory experience, along with a sales force that will enable KHK to launch its own pipeline of products in those markets. Several suitors have approached ProStrakan in recent months, but KHK was the best fit in terms of complementary product portfolios and geographic presence, ProStrakan’s chairman, Peter Allen, says.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter